Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Factors Affecting Potential Launch of Generic Version of HIV Treatment Ziagen (Abacavir)
  • USA - English


News provided by

GenericsWeb

May 13, 2014, 04:00 ET

Share this article

Share toX

Share this article

Share toX

Sydney, Australia (PRWEB) May 13, 2014 -- GlaxoSmithKline, a major shareholder in ViiV Healthcare, reported revenue of USD1.35 billion for the combination products of Epzicom® and Trizivir® during the 2013 financial year, a 10% increase over the 2012 financial year.

  • Abacavir was developed and marketed by GlaxoSmithKline and is prescribed as either an oral tablet or as an oral solution, for use in combination with other antiretrovirals, both of which were given market approval for the US in 1998.
  • Patents which protect the Abacavir molecule per se have expired in the US, but equivalent patents are still valid in the majority of European markets and Australia until June 2014 due to granted supplementary protection certificates; and in Canada until June 2016.
  • NCE data exclusivity periods have expired in all the major territories.
  • Patent family with priority number GB8815265A (1995-03-30) is considered to be a constraint to generic competition for the co-formulated dosage forms of Abacavir/Lamivudine and Abacavir/Lamivudine/Zidovudine until at least March 2016.
  • The patent families with priority numbers GB9506489A (1997-05-17) and GB9802472A (1998-02-06), protecting different salts of Abacavir, including the hemisulphate salt, and the oral solution comprising Abacavir respectively; are not considered to be a constraint to generic competition.
  • In the US, Mylan was granted 180-day market exclusivity for Abacavir tablets preventing other generic competitors from entering the market.
  • Teva has secured market authorisation in the EU for the Abacavir/Lamivudine/Zidovudine combination, using the free base form instead of hemisulphate salt. However, no market authorisations for the single dosage form have been awarded to generic competitors in the EU.
  • Although a six month paediatric extension has been granted for US 6,417,191 (‘191) that expires in September 2016, the USFDA awarded Lupin an ANDA for the Abacavir/Lamivudine/Zidovudine tablet allowing them to launch at risk pending resolution of the litigation against them by ViiV, filed in June 2011 in the US District Court of Delaware (11-cv-00576).
  • ViiV filed a suit against Teva in the US District Court of Delaware on 5th August 2011 in relation to their ANDA for the Abacavir/Lamivudine combination (11-cv-00688 consolidated with 11-cv-00576) where Teva agreed that they infringed certain claims of US ‘191.
  • In Canada, ViiV and GlaxoSmithKline have filed suits against both Teva (T-1517-13) and Apotex (T-336-14, T-333-14, T-335-14) in the Canadian Federal Court on 31th January 2014 and 12th September 2013 respectively, after these companies filed Abbreviated New Drug Submissions for generic Abacavir.

GeneicsWeb notes that: “patent and SPC protection for the molecule, its oral tablet and solution is due to expire in most jurisdictions with the US already having a market open to generic competition. The ability to launch a two or three drug co-formulation has been tested in the US; however the wisdom of launching before any final Court decision remains to be seen. Successful launch of Abacavir generics has been possible due to the lack of litigation over the patent protecting the Abacavir hemisulphate salt. The market for HIV treatments is a multi-billion dollar industry which may prove financially viable for generic Abacavir competitors given that the three drug combo represents some of the first anti-HIV drugs to be open to generic competition.”

You can read the entire article here: http://learnabout.arkpatentintelligence.com/drug-in-focus-abacavir

ABOUT GENERICSWEB AND ARK PATENT INTELLIGENCE – THE SEARCH IS OVER
GenericsWeb is a global provider of data for the pharmaceutical sector and provides IP solutions to pharmaceutical firms in every continent. It currently supplies data to 8 of the top 10 generics firms in the world. GenericsWeb is also responsible for a series of SPC validity studies that have uncovered a string of critical SPC protection issues across Europe since 2011.

ARK PATENT INTELLIGENCE data linked by INN includes: key patents, extensions, data exclusivity, non-patent literature, marketing authorisations, dossiers, news and more. Data is linked and indexed by international non-proprietary name (INN) to ensure data integrity and reduce the risk of missed data.

Yoann Bretonnet, GenericsWeb, +61 292627696, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.